Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target lifted by Stifel Nicolaus from $500.00 to $563.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a hold rating on the pharmaceutical company’s stock.
VRTX has been the topic of several other research reports. Royal Bank Of Canada increased their target price on Vertex Pharmaceuticals from $570.00 to $576.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Canaccord Genuity Group boosted their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research report on Tuesday, August 4th. TD Cowen boosted their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a “buy” rating in a research report on Wednesday, September 23rd. Leerink Partners started coverage on Vertex Pharmaceuticals in a research note on Monday, September 21st. They issued an “outperform” rating and a $594.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 11th. They issued an “overweight” rating and a $560.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $596.11.
Check Out Our Latest Research Report on VRTX
Vertex Pharmaceuticals Stock Down 4.0%
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the business earned $4.80 earnings per share. The firm’s revenue for the quarter was up 11.8% on a year-over-year basis. Research analysts anticipate that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Vertex Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in VRTX. Almanack Investment Partners LLC. acquired a new position in Vertex Pharmaceuticals in the third quarter valued at about $510,000. M Holdings Securities Inc. bought a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $1,885,000. Candriam S.C.A. raised its position in shares of Vertex Pharmaceuticals by 6.7% during the third quarter. Candriam S.C.A. now owns 212,933 shares of the pharmaceutical company’s stock worth $111,730,000 after purchasing an additional 13,428 shares during the period. Cooper Haims Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $203,000. Finally, Ethic Inc. raised its position in shares of Vertex Pharmaceuticals by 8.6% during the third quarter. Ethic Inc. now owns 22,744 shares of the pharmaceutical company’s stock worth $11,891,000 after purchasing an additional 1,797 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.
Key Stories Impacting Vertex Pharmaceuticals
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, topping estimates, supported by Vertex’s cystic-fibrosis franchise and growth from newer medicines including CASGEVY and JOURNAVX. The company also raised its 2026 sales outlook. Read More.
- Positive Sentiment: Management expressed confidence in the anticipated launch of povetacicept for IgA nephropathy ahead of an FDA decision, an important potential growth driver beyond cystic fibrosis. Several analysts also raised their price targets after the results. Read More. · Read More.
- Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates. Acquisition and launch-related spending weighed on profit, while sales of the newer pain drug JOURNAVX were described as light—dampening the market’s reaction to the revenue beat. Read More.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.
Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.
Further Reading
- Five stocks we like better than Vertex Pharmaceuticals
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
